Controlled Substances Act

The Controlled Substances Act (CSA), Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970, is the legal foundation of the government's fight against abuse of drugs and other substances. This law is a consolidation of numerous laws regulating the manufacture and distribution of narcotics, stimulants, depressants, hallucinogen anabolic steroids and chemicals used in the illicit production of controlled substances.

Controlling Drugs or Other Substances

FORMAL SCHEDULING

The CSA places all substances which were in some manner regulated under existing Federal law into one of five schedules. This placement is based upon the substance's medical use, potential for abuse, and safety or dependence liability. The Act also provides a mechanism for substances to be controlled, or added to a schedule; decontrolled, or removed from control; and rescheduled or transferred from one schedule to another. The procedure for these actions is found in Section 201 of the Act (21 U.S.C. 811).

Proceedings to add, delete, or change the schedule of a drug or other substance may be initiated by the Drug Enforcement Administration (DEA), the Department of Health and Human Services (HHS), or by petition from any interested person: the manufacturer of a drug, a medical society or association, a pharmacy association, a public interest group concerned with drug abuse, a state or local government agency, or an individual citizen. When a petition is received by DEA, the agency begins its own investigation of the drug.

The agency may also begin an investigation of a drug at any time based upon information received from law enforcement laboratories, state and local law enforcement and regulatory agencies, or other sources of information.

Once DEA has collected the necessary data, the Administrator of DEA, by authority of the Attorney General, requests from HHS a scientific and medical evaluation and recommendation as to whether the drug or other substance should be controlled or removed from control. This request is sent to the Assistant Secretary of Health of HHS. HHS solicits information from the Commissioner of the Food
and Drug Administration (FDA), evaluations and recommendations from the National Institute on Drug Abuse, and on occasion from the scientific and medical community at large. The Assistant Secretary, by authority of the Secretary, compiles the information and transmits back to DEA a medical and scientific evaluation regarding the drug or other substance, a recommendation as to whether the drug should be controlled, and in what schedule it should be placed.

The medical and scientific evaluations are binding on DEA with respect to scientific and medical matters. The recommendation on scheduling is binding only to the extent that if HHS recommends that the substance not be controlled, DEA may not control the substance.

Once DEA has received the scientific and medical evaluation from HHS, the Administrator will evaluate all available data and make a final decision whether to propose that a drug or other substance should be controlled and into which schedule it should be placed.

The threshold issue is whether the drug or other substance has potential for abuse. If a drug does not have a potential for abuse, it cannot be controlled. Although the term “potential for abuse” is not defined in the CSA, there is much discussion of the term in the legislative history of the Act. The following items are indicators that a drug or other substance has a potential for abuse:

1. There is evidence that individuals are taking the drug or other substance in amounts sufficient to create a hazard to their health or to the safety of other individuals or to the community; or

2. There is significant diversion of the drug or other substance from legitimate drug channels; or

3. Individuals are taking the drug or other substance on their own initiative rather than on the basis of medical advice from a practitioner licensed by law to administer such drugs; or

4. The drug is a new drug so related in its action to a drug or other substance already listed as having a potential for abuse to make it likely that the drug will have the same potential for abuse as such drugs, thus making it reasonable to assume that there may be significant diversions from legitimate channels, significant use contrary to or without medical advice, or that it has a substantial capability of creating hazards to the health of the user or to the safety of the community. Of course, evidence of actual abuse of a substance is indicative that a drug has a potential for abuse.

In determining into which schedule a drug or other substance should be placed, or whether a substance should be decontrolled or rescheduled, certain factors are required to be considered. Specific findings are not required for each factor. These factors are listed in Section 201 (c), [21 U.S.C. 811 (c)], of the CSA and are as follows:

1. The drug’s actual or relative potential for abuse.

2. Scientific evidence of the drug’s pharmacological effects. The state of knowledge with respect to the effects of a specific drug is, of course, a major consideration. For example, it is vital to know whether or not a drug has a hallucinogenic effect if it is to be controlled because of that. The best available knowledge of the pharmacological properties of a drug should be considered.

3. The state of current scientific knowledge regarding the substance.
Criteria (2) and (3) are closely related. However, (2) is primarily concerned with pharmacological effects and (3) deals with all scientific knowledge with respect to the substance.

(4) Its history and current pattern of abuse. To determine whether or not a drug should be controlled, it is important to know the pattern of abuse of that substance, including the socio-economic characteristics of the segments of the population involved in such abuse.

(5) The scope, duration, and significance of abuse. In evaluating existing abuse, the Administrator must know not only the pattern of abuse but whether the abuse is widespread. In reaching his decision, the Administrator should consider the economics of regulation and enforcement attendant to such a decision. In addition, he should be aware of the social significance and impact of such a decision upon those people, especially the young, that would be affected by it.

(6) What, if any, risk there is to the public health. If a drug creates dangers to the public health, in addition to or because of its abuse potential, then these dangers must also be considered by the Administrator.

(7) The drug’s psychic or physiological dependence liability. There must be an assessment of the extent to which a drug is physically addictive or psychologically habit-forming, if such information is known.

(8) Whether the substance is an immediate precursor of a substance already controlled. The CSA allows inclusion of immediate precursors on this basis alone into the appropriate schedule and thus safeguards against possibilities of clandestine manufacture.

After considering the above listed factors, the Administrator must make specific findings concerning the drug or other substance. This will determine into which schedule the drug or other substance will be placed. These schedules are established by the CSA.

They are as follows:

**Schedule I**

- The drug or other substance has a high potential for abuse.
- The drug or other substance has no currently accepted medical use in treatment in the United States.
- There is a lack of accepted safety for use of the drug or other substance under medical supervision.
- Some Schedule I substances are heroin, LSD, marijuana, and methaqualone.

**Schedule II**

- The drug or other substance has a high potential for abuse.
- The drug or other substance has a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions.
- Abuse of the drug or other substance may lead to severe psychological or physical dependence.
- Schedule II substances include morphine, PCP, cocaine, methadone, and methamphetamine.

**Schedule III**

- The drug or other substance has a potential for abuse less than the drugs or other substances
in Schedules I and II.

- The drug or other substance has a currently accepted medical use in treatment in the United States.
- Abuse of the drug or other substance may lead to moderate or low physical dependence or high high psychological dependence.
- Anabolic steroids, codeine and hydrocodone with aspirin or Tylenol®, and some barbiturates are Schedule III substances.

Schedule IV

- The drug or other substance has a low potential for abuse relative to the drugs or other substances in Schedule III.
- The drug or other substance has a currently accepted medical use in treatment in the United States.
- Abuse of the drug or other substance may lead to limited physical dependence or psychological dependence relative to the drugs or other substances in Schedule III.
- Included in Schedule IV are Darvon®, Talwin®, Equanil®, Valium® and Xanax®.

Schedule V

- The drug or other substance has a low potential for abuse relative to the drugs or other substances in Schedule IV.
- The drug or other substance has a currently accepted medical use in treatment in the United States.
- Abuse of the drug or other substances may lead to limited physical dependence or psychological dependence relative to the drugs or other substances in Schedule IV.
- Over-the-counter cough medicines with codeine are classified in Schedule V.

When the Administrator of DEA has determined that a drug or other substance should be controlled, decontrolled, or rescheduled, a proposal to take action is published in the Federal Register. The proposal invites all interested persons to file comments with DEA. Affected parties may also request a hearing with DEA. If no hearing is requested, DEA will evaluate all comments received and publish a final order in the Federal Register, controlling the drug as proposed or with modifications based upon the written comments filed. This order will set the effective dates for imposing the various requirements imposed under the CSA.

If a hearing is requested, DEA will enter into discussions with the party or parties requesting a hearing in an attempt to narrow the issue for litigation. If necessary, a hearing will then be held before an Administrative Law Judge. The judge will take evidence on factual issues and hear arguments on legal questions regarding the control of the drug. Depending on the scope and complexity of the issues, the hearing may be brief or quite extensive. The Administrative Law Judge, at the close of the hearing, prepares findings of fact and conclusions of law and a recommended decision which is submitted to the Administrator of DEA. The Administrator will review these documents, as well as the underlying material, and prepare his/her own findings of fact and conclusions of law (which may or may not be the same as those drafted by the Administrative Law Judge). The Administrator then publishes a final order in the Federal Register either scheduling the drug or other substance or declining to do so.

Once the final order is published in the Federal Register, interested parties have 30 days to appeal to a U.S. Court of Appeals to challenge the order. Findings of fact by the Administrator are deemed...
conclusive if supported by "substantial evidence". The order imposing controls is not stayed during the appeal, however, unless so ordered by the Court.

Emergency or Temporary Scheduling

The CSA was amended by the Comprehensive Crime Control Act of 1984. This Act included a provision which allows the Administrator of DEA to place a substance, on a temporary basis, into Schedule I when necessary to avoid an imminent hazard to the public safety.

This emergency scheduling authority permits the scheduling of a substance which is not currently controlled, is being abused, and is a risk to the public health while the formal rule making procedures described in the CSA are being conducted. This emergency scheduling applies only to substances with no accepted medical use. A temporary scheduling order may be issued for one year with a possible extension of up to six months if formal scheduling procedures have been initiated. The proposal and order are published in the Federal Register as are the proposals and orders for formal scheduling. [21 U.S.C. 811 (h)]

Controlled Substance Analogues

A new class of substances was created by the Anti-Drug Abuse Act of 1986. Controlled substance analogue are substances which are not controlled substances, but may be found in the illicit traffic. They are structurally or pharmacologically similar to Schedule I or II controlled substances and have no legitimate medical use. A substance which meets the definition of a controlled substance analogue and is intended for human consumption is treated under the CSA as if it were a controlled substance in Schedule I. [21 U.S.C. 802(32)(A), 21 U.S.C. 813]

International Treaty Obligations

United States treaty obligations may require that a drug or other substance be controlled under the CSA, or rescheduled if existing controls are less stringent than those required by a treaty. The procedures for these scheduling actions are found in Section 201 (d) of the Act. [21 U.S.C. 811 (d)]
The United States is a party to the Single Convention on Narcotic Drugs of 1961, designed to establish effective control over international and domestic traffic in narcotics, coca leaf, cocaine, and cannabis. A second treaty, the Convention on Psychotropic Substances of 1971, which entered into force in 1976, is designed to establish comparable control over stimulants, depressants, and hallucinogens. Congress ratified this treaty in 1980.

REGULATION

The CSA creates a closed system of distribution for those authorized to handle controlled substances. The cornerstone of this system is the registration of all those authorized by DEA to handle controlled substances. All individuals and firms that are registered are required to maintain complete and accurate inventories and records of all transactions involving controlled substances, as well as security for the storage of controlled substances.

Registration

Any person who handles or intends to handle controlled substances must obtain a registration issued by DEA. A unique number is assigned to each legitimate handler of controlled drugs: importer, exporter, manufacturer, distributor, hospital, pharmacy, practitioner, and researcher. This number must be made available to the supplier by the customer prior to the purchase of a controlled substance. Thus, the opportunity for unauthorized transactions is greatly diminished.

Record keeping

The CSA requires that complete and accurate records be kept of all quantities of controlled substances manufactured, purchased, and sold. Each substance must be inventoried every two years. Some limited exceptions to the record keeping requirements may apply to certain categories of registrants.

From these records it is possible to trace the flow of any drug from the time it is first imported or manufactured through the distribution level, to the pharmacy or hospital that dispensed it, and then to the actual patient who received the drug. The mere existence of this requirement is sufficient to discourage many forms of diversion. It actually serves large drug corporations as an internal check to uncover diversion, such as pilferage by employees.

There is one distinction between scheduled items for record keeping requirements. Records for Schedule I and II drugs must be kept separate from all other records of the handler; records for Schedule III, IV, and V substances must be kept in a "readily retrievable" form. The former method allows for more expeditious investigations involving the highly abusable substances in Schedules I and II.

Distribution

The keeping of records is required for distribution of a controlled substance from one manufacturer to another, from manufacturer to distributor, and from distributor to dispenser. In the case of Schedule I
and II drugs, the supplier must have a special order form from the customer. This order form (DEA Form 222) is issued by DEA only to persons who are properly registered to handle Schedules I and II. The form is preprinted with the name and address of the customer. The drugs must be shipped to this name and address. The use of this device is a special reinforcement of the registration requirement; it makes doubly certain that only authorized individuals may obtain Schedule I and II drugs. Another benefit of the form is the special monitoring it permits. The form is issued in triplicate: the customer keeps one copy; two copies go to the supplier who, after filling the order, keeps a copy and forwards the third copy to the nearest DEA office. For drugs in Schedules III, IV, and V, no order form is necessary. The supplier in each case, however, is under an obligation to verify the authenticity of the customer. The supplier is held fully accountable for any drugs which are shipped to a purchaser who does not have a valid registration. Manufacturers must submit periodic reports of the Schedule I and II controlled substances they produce in bulk and dosage forms. They also report the manufactured quantity and form of each narcotic substance listed in Schedules III, IV, and V, as well as the quantity of synthesized psychotropic substances listed in Schedules I, II, III, and IV. Distributors of controlled substances must report the quantity and form of all their transactions of controlled drugs listed in Schedules I and II and narcotics listed in Schedule III. Both manufacturers and distributors are required to provide reports of their annual inventories of these controlled substances. This data is entered into a system called the Automated Reports and Consolidated Orders System (ARCOS). It enables DEA to monitor the distribution of controlled substances throughout the country, and to identify retail level registrants that receive unusual quantities of controlled substances.

Dispensing to Patients

The dispensing of a controlled substance is the delivery of the controlled substance to the ultimate user, who may be a patient or research subject. Special control mechanisms operate here as well. Schedule I drugs are those which have no currently accepted medical use in the United States; they may, therefore, be used in the United States only in research situations. They generally are supplied by only a limited number of firms to properly registered and qualified researchers. Controlled substances may be dispensed by a practitioner by direct administration, by prescription, or by dispensing from office supplies.

Records must be maintained by the practitioner of all dispensing of controlled substances from office supplies and of certain administrations. The CSA does not require the practitioner to maintain copies of prescriptions, but certain states require the use of multiple copy prescriptions for Schedule II and other specified controlled substances.
The determination to place drugs on prescription is within the jurisdiction of the FDA. Unlike other prescription drugs, however, controlled substances are subject to additional restrictions. Schedule II prescription orders must be written and signed by the practitioner; they may not be telephoned into the pharmacy except in an emergency. In addition, a prescription for a Schedule II drug may not be refilled; the patient must see the practitioner again in order to obtain more drugs. For Schedule III and IV drugs, the prescription order may be either written or oral (that is, by telephone to the pharmacy). In addition, the patient may (if authorized by the practitioner) have the prescription refilled up to five times and at anytime within six months from the date of the initial dispensing.

Schedule V includes some prescription drugs and many over-the-counter narcotic preparations, including antitussives and antidiarrheals. Even here, however, the law imposes restrictions beyond those normally required for the over-the-counter sales; for example, the patient must be at least 18 years of age, must offer some form of identification, and have his or her name entered into a special log maintained by the pharmacist as part of a special record.

Quotas

DEA limits the quantity of Schedule I and II controlled substances which may be produced in the United States in any given calendar year. By utilizing available data on sales and inventories of these controlled substances, and taking into account estimates of drug use age provided by the FDA, DEA establishes annual aggregate production quotas for Schedule I and II controlled substances. The aggregate production quota is allocated among the various manufacturers who are registered to manufacture the specific drug. DEA also allocates the amount of bulk drug which may be procured by those companies which prepare the drug into dosage units.

Security

DEA registrants are required by regulation to maintain certain security for the storage and distribution of controlled substances. Manufacturers and distributors of Schedule I and II substances must store controlled substances in specially constructed vaults or highly rated safes, and maintain electronic security for all storage areas. Lesser physical security requirements apply to retail level registrants such as hospitals and pharmacies. All registrants are required to make every effort to ensure that controlled substances in their possession are not diverted into the illicit market. This requires operational as well as physical security. For example, registrants are responsible for ensuring that controlled substances are distributed only to other registrants that are authorized to receive them, or to legitimate patients and consumers.

PENALTIES

The CSA provides penalties for unlawful manufacturing, distribution, and dispensing of controlled substances. The penalties are basically determined by the schedule of the drug or other substance, and sometimes are specified by drug name, as in the case of marijuana. As the statute has been amended since its initial passage in 1970, the penalties have been altered by Congress. The following charts are an overview of the penalties for trafficking or unlawful distribution of controlled substances. This is not inclusive of the penalties provided under the CSA.

User Accountability /Personal Use Penalties

On November 19, 1988, Congress passed the Anti-Drug Abuse Act of 1988, P. L. 100-690. Two sections of this Act represent the Federal Government's attempt to reduce drug abuse by dealing not just with the person who sells the illegal drug, but also with the person who buys it. The first new section is titled "User Accountability" and is codified at 21 U.S.C. § 862 and various sections of Title 42, U.S.C. The second involves "personal use amounts" of illegal drugs, and

**User Accountability**

The purpose of User Accountability is to not only make the public aware of the Federal Government’s position on drug abuse, but to describe new programs intended to decrease drug abuse by holding drug abusers personally responsible for their illegal activities, and imposing civil penalties on those who violate drug laws.

It is important to remember that these penalties are in addition to the criminal penalties drug abusers are already given, and do not replace those criminal penalties.

The new User Accountability programs call for more instruction in schools, kindergarten through senior high, to educate children on the dangers of drug abuse. These programs will include participation by students, parents, teachers, local businesses and the local, state and Federal Government.

User Accountability also targets businesses interested in doing business with the Federal Government. This program requires those businesses to maintain a drug-free workplace, principally through educating employees on the dangers of drug abuse, and by informing employees of the penalties they face if they engage in illegal drug activity on company property.

There is also a provision in the law that makes public housing projects drug-free by evicting those residents who allow their units to be used for illegal drug activity, and denies Federal benefits, such as housing assistance and student loans, to individuals convicted of illegal drug activity. Depending on the offense, an individual may be prohibited from ever receiving any benefit provided by the Federal Government.

**Personal Use Amounts**

This section of the 1988 Act allows the government to punish minor drug offenders without giving the offender a criminal record if the offender is in possession of only a small amount of drugs. This law is designed to impact the “user” of illicit drugs, while simultaneously saving the government the costs of a full-blown criminal investigation.

Under this section, the government has the option of imposing only a civil fine on individuals possessing only a small quantity of an illegal drug. Possession of this small quantity, identified as a "personal use amount" carries a civil fine of up to $10,000.

In determining the amount of the fine in a particular case, the drug offender’s income and assets will be considered. This is accomplished through an administrative proceeding rather than a criminal trial, thus reducing the exposure of the offender to the entire criminal justice system, and reducing the costs to the offender and the government.

The value of this section is that it allows the government to punish a minor drug offender without saddling the offender with a criminal record. This section also gives the drug offender the opportunity to fully redeem himself or herself, and have all public record of the proceeding destroyed. If this was the drug offender’s first offense, and the offender has paid all fines, can pass a drug test, and has not been convicted of a crime after three years, the offender can request that all proceedings be dismissed.

If the proceeding is dismissed, the drug offender can lawfully say he or she had never been prosecuted, either criminally or civilly, for a drug offense.

Congress has imposed two limitations on this section’s use. It may not be used if (1) the drug offender
has been previously convicted of a Federal or state drug offense; or (2) the offender has already been fined twice under this section.
<table>
<thead>
<tr>
<th>Schedule</th>
<th>Quantity</th>
<th>1st Offense</th>
<th>2nd Offense</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schedule II</td>
<td>5 - 49 gms pure or 50-499 gms mixture</td>
<td>Not less than 5 yrs and not more than 5 yrs. If death or serious injury, not less than 20 yrs or more than life. Fine of not more than $2 million if an individual, $5 million if other than an individual.</td>
<td>Not more than 10 yrs. Fine not more than $500,000 individual, $1 million not individual.</td>
</tr>
<tr>
<td>Heroin</td>
<td>100-999 gms mixture</td>
<td>Not less than 10 yrs and not more than 10 yrs. If death or serious injury, not less than 20 yrs or more than life. Fine of not more than $4 million if an individual, $10 million if other than an individual.</td>
<td>Not less than 20 yrs and not more than life. If death or serious injury, not less than 20 yrs or more than life. Fine of not more than $8 million if an individual, $20 million if other than an individual.</td>
</tr>
<tr>
<td>Schedule II</td>
<td>500-4,999 gms mixture</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cocaine Base</td>
<td>5 - 49 gms mixture</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schedule II</td>
<td>10 - 99 gms pure or 100-999 gms mixture</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCP</td>
<td>50 gms or more pure or 500 gms or more mixture</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LSD</td>
<td>1 - 9 gms mixture</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schedule I</td>
<td>40-399 gms mixture</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fentanyl</td>
<td>Any</td>
<td>1st Offense</td>
<td>2nd Offense</td>
</tr>
<tr>
<td>Schedule I</td>
<td>Any</td>
<td>Not more than 20 yrs. If death or serious injury, not less than 20 yrs or more than life. Fine $1 million individual, $5 million not individual.</td>
<td>Not more than 10 yrs. Fine not more than $500,000 individual, $1 million not individual.</td>
</tr>
<tr>
<td>Fentanyl Analogue</td>
<td>Any</td>
<td>Not more than 30 yrs. If death or serious injury, not less than 20 yrs or more than life. Fine $2 million individual, $10 million not individual.</td>
<td>Not more than 6 yrs. Fine not more than $500,000 individual, $2 million not individual.</td>
</tr>
<tr>
<td>Others</td>
<td>1 gms or more mixture</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Schedules I &amp; II)</td>
<td>Any</td>
<td>Not more than 20 yrs. If death or serious injury, not less than 20 yrs or more than life. Fine of not more than $2 million if an individual, $5 million if other than an individual.</td>
<td>Not more than 10 yrs. Fine not more than $500,000 individual, $1 million not individual.</td>
</tr>
<tr>
<td>Others</td>
<td>Any</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schedule III</td>
<td>Any</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schedule IV</td>
<td>Any</td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>Any</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
# Federal Trafficking Penalties - Marijuana*

<table>
<thead>
<tr>
<th>Quantity</th>
<th>1st Offense</th>
<th>2nd Offense</th>
</tr>
</thead>
</table>
| 1,000 lbs or more mixtures; or 1,000 or more plants | • Not less than 10 years, not more than life  
• If death or serious injury, not less than 20 years, not more than life  
• Fine not more than $4 million individual, $10 million other than individual | • Not less than 20 years, not more than life  
• If death or serious injury, then life  
• Fine not more than $8 million individual, $20 million other than individual |
| 100 lbs to 999 lbs mixture; or 100-999 plants | • Not less than 5 years, not more than 40 years  
• If death or serious injury, not less than 20 years, not more than life  
• Fine not more than $2 million individual, $5 million other than individual | • Not less than 10 years, not more than life  
• If death or serious injury, then life  
• Fine not more than $4 million individual, $10 million other than individual |
| 50 to 99 lbs mixture      | • Not more than 20 years  
• If death or serious injury, not less than 20 years, not more than life  
• Fine $1 million individual, $5 million other than individual | • Not more than 30 years  
• If death or serious injury, then life  
• Fine $2 million individual, $10 million other than individual |
| 50 to 99 plants           |                                                                             |                                                                             |
| More than 10 lbs          |                                                                             |                                                                             |
| More than 1 lb            |                                                                             |                                                                             |
| Less than 50 lbs mixture  | • Not less than 5 years  
• Fine not more than $250,000.  
$1 million other than individual | • Not less than 10 years  
• Fine $500,000 individual,  
$2 million other than individual |
| 1 to 49 plants            |                                                                             |                                                                             |
| 10 lbs or less            |                                                                             |                                                                             |
| 1 kg or less              |                                                                             |                                                                             |

*Includes Hashish and Hashish Oil

(Marijuana is a Schedule I Controlled Substance)
# Regulatory Requirements

## Controlled Substances

<table>
<thead>
<tr>
<th>Schedule I</th>
<th>Schedule II</th>
<th>Schedule III</th>
<th>Schedule IV</th>
<th>Schedule V</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Registration</strong></td>
<td>Required</td>
<td>Required</td>
<td>Required</td>
<td>Required</td>
</tr>
<tr>
<td><strong>Recording</strong></td>
<td>Separate</td>
<td>Separate</td>
<td>Readily retrievable</td>
<td>Readily retrievable</td>
</tr>
<tr>
<td><strong>Distribution Regulations</strong></td>
<td>Order forms</td>
<td>Order forms</td>
<td>Records required</td>
<td>Records required</td>
</tr>
<tr>
<td><strong>Dispensing Limits</strong></td>
<td>Research use only</td>
<td>Rx: written; no refills</td>
<td>Rx: written or oral; refills Note 1</td>
<td>Rx: written or oral; refills Note 1</td>
</tr>
<tr>
<td><strong>Storage</strong></td>
<td>Vault/safe</td>
<td>Vault/safe</td>
<td>Secure storage area</td>
<td>Secure storage area</td>
</tr>
<tr>
<td><strong>Import/Export</strong></td>
<td>Yes</td>
<td>Yes</td>
<td>NO but some drugs limited by Schedule II</td>
<td>NO but some drugs limited by Schedule II</td>
</tr>
<tr>
<td><strong>Import/Export: Non-V applicable</strong></td>
<td>Permit</td>
<td>Permit</td>
<td>Permit</td>
<td>Permit</td>
</tr>
<tr>
<td><strong>Report to DEA by Manufacturer/Distributor</strong></td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Manufacturer only</td>
</tr>
<tr>
<td><strong>Report to DEA by Manufacturer/Distributor: Non-National</strong></td>
<td>Yes</td>
<td>Yes</td>
<td>Note 3</td>
<td>Note 3</td>
</tr>
</tbody>
</table>

**Note 1**: With medical authorization, refills up to 5 in 6 months  
**Note 2**: Manufacturer reports required for non-medical drugs

---

8/6/2003

http://www.usdoj.gov/dea/pubs/abuse/abuse 02.htm